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HeartGlypican-3 (Gpc3) is a heparan sulfate proteoglycan (HSPG) expressed widely during vertebrate
development. Loss-of-function mutations cause Simpson–Golabi–Behmel syndrome (SGBS), a rare and
complex congenital overgrowth syndrome with a number of associated developmental abnormalities
including congenital heart disease. We found that Gpc3-deﬁcient mice display a high incidence of congenital
cardiac malformations like ventricular septal defects, common atrioventricular canal and double outlet right
ventricle. In addition we observed coronary artery ﬁstulas, which have not been previously reported in SGBS.
Coronary artery ﬁstulas are noteworthy because little is known about the molecular basis of this
abnormality. Formation of the coronary vascular plexus in Gpc3-deﬁcient embryos was delayed compared to
wild-type, and consistent with GPC3 functioning as a co-receptor for ﬁbroblast growth factor-9 (FGF9), we
found a reduction in Sonic Hedgehog (Shh) mRNA expression and signaling in embryonic mutant hearts.
Interestingly, we found an asymmetric reduction in SHH signaling in cardiac myocytes, as compared with
perivascular cells, resulting in excessive coronary artery formation in the Gpc3-deﬁcient animals. We
hypothesize that the excessive development of coronary arteries over veins enables the formation of
coronary artery ﬁstulas. This work has broad signiﬁcance to understanding the genetic basis of coronary
development and potentially to molecular mechanisms relevant to revascularization following ischemic
injury to the heart.
© 2009 Elsevier Inc. All rights reserved.Introduction
HSPGs are expressedwidely on both the surface of cells and within
the extracellularmatrix where they bind andmodify the functions of a
diverse array of ligands. Mutations in the genes encoding both
enzymes in the heparan sulfate biosynthetic pathway, as well as those
encoding speciﬁc core proteins that bear heparan sulfate, have been
shown to result in signiﬁcant developmental abnormalities due to
defects in growth factor signaling (Perrimon and Bernﬁeld, 2000).
Although heparan sulfate itself is ubiquitous on cell surfaces this post-
synthetic modiﬁcation occurs predominantly on the proteins encoded
by members of two gene families: syndecans (Saunders et al., 1989)
and glypicans (David et al., 1990).ashington University School
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ders).
tudies.
ll rights reserved.There are six members of the vertebrate glypican gene family
(Paine-Saunders et al., 1999; Veugelers et al., 1999). These glypicans
share a commonmechanism of attachment to the cell surface through
glycophosphatidylinositol linkages, and homologies within the core
protein primary sequences suggest the existence of subfamilies of
structurally related glypicans (Paine-Saunders et al., 1999; Veugelers
et al., 1999). Multiple studies have provided evidence for the
involvement of various glypicans in the modulation of cell signaling,
including speciﬁcally several studies both in vitro and in vivo
suggested a function for glypican-3 (Gpc3) in the BMP (Paine-
Saunders et al., 2000), Hedgehog (Capurro et al., 2008), Wnt (De
Cat et al., 2003; Song et al., 2005) and FGF (Grisaru et al., 2001)
signaling pathways.
Loss-of-function mutations in GPC3 cause an X-linked disorder in
humans known as Simpson–Golabi–Behmel syndrome (SGBS), a
disorder associated with both pre- and postnatal overgrowth, a
predisposition to certain childhood cancers and a complex assortment
of developmental birth defects including cardiac malformation. In the
most comprehensive review of cardiac anomalies in patients with a
clinical diagnosis of SGBS, Lin et al. (1999) described 101 patients (89
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an abnormality of cardiac structure or function and 26 who had an
anatomic heart defect. Of patients less than 3 years of age, death was
associated with a cardiac abnormality in 23%. When only patients
with a documented GPC3 gene mutation were considered, 46% had a
cardiac abnormality.
Gpc3 knockout mice have not previously been evaluated for
cardiac defects, but we suspected them given a consistent observation
of as much as a 50% perinatal lethality in Gpc3-deﬁcient animals
(Paine-Saunders et al., 2000). To determine the potential effect of
Gpc3 loss of function on cardiac development, we collected newborn
(P0) mouse pups and performed a detailed histological evaluation of
their cardiac anatomy. As expected, we found a high incidence of
defects as seen in human patients with SGBS with ventricular septal
defects (VSD)most common. Other structural defects included double
outlet right ventricle and common atrioventricular canal. To our
surprise, we found an especially high frequency of coronary artery
ﬁstulas, a defect rarely reported in associationwithmutations of other
cardiac developmental genes and for which the molecular basis is
poorly understood. We therefore evaluated the consequence of the
loss of Gpc3 function to the process of coronary vascular development.
Loss of Gpc3 function causes a delay in coronary vascular plexus
formation and a reduction in downstream Shh signaling, consistent
with a loss of Gpc3 function as a co-receptor for FGF9 signaling in the
developing heart. Loss of Gpc3 function is associated with a selective
reduction of SHH signaling in the cardiomyocytes, with relative
preservation of signaling in the perivascular cells. This correlates with
an excessive development of coronary arteries relative to veins that
we propose is the pathogenic mechanism for the formation of
coronary artery ﬁstulas.
Methods
Animals
These experiments made use of the tm108 targeted null allele of
Gpc3 as has been previously described (Paine-Saunders et al., 2000)
and bred onto a pure background of C57Bl6. Because Gpc3 is an
X-linked allele, we restricted our analysis to male animals either wild-
type or hemizygous null for Gpc3 (Gpc3/Y). Genotypes of embryos
were determined by PCR for the wild-type and Gpc3-mutant alleles,
and sex was determined by PCR for Sry, both as previously described
(Paine-Saunders et al., 2000).
Cardiac histopathology
Neonatal pups were collected each morning within hours of birth
to prevent cannibalization of animals that have hemodynamically
signiﬁcant congenital heart disease. The pups were euthanized. The
thorax was ﬁxed in 10% neutral buffered formalin and then
transferred to 70% ethanol. Fixed hearts were dissected free and
embedded in parafﬁn. The hearts were entirely sectioned in the
frontal plane at 6 μm thickness. The sections were stained with
hematoxylin and eosin, and two individuals independently inspected
each heart under a 5× microscope objective for defects.
Non-radioactive in situ hybridization
Slides containing zinc ﬁxed, parafﬁn-embedded hearts or torsos
from embryonic day 12.5–14.5 (E12.5–14.5) were deparafﬁnized and
hydrated. Sections were ﬁxed in 4% paraformaldehyde in PBS for 25
min, rinsed once in PBS, and then digested with 10 μg/ml proteinase K
for 10 min at 37 °C. The digestion was stopped by incubating for 10
min in 0.2% glycine in PBS. Slides were then washed twice in PBS,
acetylated in 0.1 M triethanolamine (pH 8.0) and 0.25% acetic
anhydride for 10 min, and rinsed once more in PBS, before incubatingat 65 °C for 4 h in prehybridization buffer, containing 50% formamide,
1.3× SSC, 5 mM EDTA, 50 μg/ml yeast tRNA, 0.2% Tween 20 and 0.5%
CHAPS. Hybridization was carried out using digoxigenin-labeled
antisense probes at 65 °C for 16–20 h in a humidity chamber. Slides
were rinsed and treated with 20 μg/ml RNase A for 30 min at 37 °C
and washed twice with 2× SSC, 0.1% CHAPS for 10 min at 65 °C, then
twice with 0.2× SSC, 0.1% CHAPS for 10min at 65 °C, and then twice in
KTBT buffer containing 50mMTris (pH 7.5), 150mMNaCl, 10mMKCl
and 1% Triton X-100 for 5 min. Sections were blocked for 2 h at 4 °C in
KTBT with 0.1% Blocking Reagent (Roche) and 20% sheep serum
(Sigma) and then incubated with alkaline phosphatase labeled anti-
digoxigenin (Roche) for 16–20 h, washed with KTBT ﬁve times for 10
min, and then washed with NTMT containing 40 mM Tris (pH 9.5),
100 mM NaCl, 40 mM MgCl and 0.2% Tween 20 twice for 5 min.
Development was with BCIP/NBT (Vector Labs) and slides were
counterstained with Nuclear Fast Red (Vector Labs).
Whole-mount in situ hybridization
E13.5 hearts were ﬁxed in 4% paraformaldehyde and processed
according to the protocol described by Colvin et al. (2001) with the
following modiﬁcations: a 0.2% glycine wash was included after the
proteinase K digestion, the hybridization solution did not contain any
heparin and we included 0.1% Blocking Reagent (Roche) in the
antibody blocking buffer.
Whole-mount immunohistochemistry
E13.5 hearts were ﬁxed in 4% paraformaldehyde and processed
according to the protocol described by White et al. (2007) with the
following modiﬁcations: a 0.1% Blocking Reagent (Roche) was added
to the blocking buffer, the secondary antibody and subsequent steps
were from an ABC elite kit (Vector Labs) and the hearts were
incubated in the ABC reagent overnight at 4 °C.
Results
Loss of Gpc3 function results in structural heart defects in mice including
coronary artery ﬁstulas
Gpc3 is widely expressed in the cardiomyocytes of the
embryonic heart, and human patients with SGBS commonly have
congenital heart defects (Lin et al., 1999) thus demonstrating the
importance of Gpc3 function to cardiac development. To assess the
effect of the loss of Gpc3 function in cardiac development, a detailed
histological examination was performed of 30 hearts from newborn
(P0) mice either wild-type (n=14) or deﬁcient for Gpc3 (n=16).
While the wild-type hearts were all normal, there was a high
incidence of heart defects in the Gpc3-deﬁcient animals (69%)
representing a variety of abnormalities with the most common
being VSD (5/16 hearts; 4 perimembranous, 1 inlet). Defects of the
outﬂow tract and atrioventricular canal development were also
found and one mutant animal had a double outlet right ventricle.
Whereas the pulmonary artery and aorta normally arise from the
right and left ventricles, respectively (Figs. 1A and B), in the double
outlet right ventricle the pulmonic valve (Fig. 1C, arrowhead) was
ventral and leftward to the aortic valve, which also arose from the
right ventricle (Fig. 1D, arrowhead). The VSD was in the subaortic
position, and there was ﬁbrous discontinuity between the aortic and
mitral valves (not shown). In contrast to the separate tricuspid and
mitral valves, as seen in a wild-type littermate (Fig. 1E), two mutant
animals had a common atrioventricular canal with leaﬂets of the
common valve bridging the two ventricles (Fig. 1F). Fig. 1G shows
an example of a perimembranous VSD and a summary of the
cardiac defects and their frequency in Gpc3-deﬁcient animals are
shown (Fig. 1H).
Fig. 1. Congenital heart defects in Gpc3-deﬁcient hearts. (A and B) The normal origins of the pulmonary artery and aorta (arrowheads) from the right and left ventricles, respectively,
are shown. (C and D) Double outlet right ventricle in a Gpc3/Ymouse. Both great arteries originate from the right ventricle. The pulmonic valve (C, arrowhead) is ventral and leftward
to the aortic valve (D, arrowhead). (E) Separate tricuspid and mitral valves are shown in this wild-type mouse. (F) Common atrioventricular canal in a Gpc3/Ymouse. The common
atrioventricular valve (arrowhead) is shown. (G) Perimembranous VSD in a Gpc3/Ymouse (arrowhead). (H) Summary of observed cardiac phenotypes in Gpc3/Y mice. Of the ﬁve
VSDs, four were small perimembranous and one was a small inlet. ⁎, one heart with a coronary artery ﬁstula had a small perimembranous VSD. The double outlet right ventricle was
associated with a subaortic VSD. We observed one patent ductus arteriosus (PDA). All 14 wild-type littermate control hearts were structurally normal. Scale bar, 500 μm.
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Gpc3-deﬁcient animals (Fig. 1H). In contrast to the normal proximal
left anterior descending (LAD) and circumﬂex (CIRC) arteries in a
wild-type littermate (Fig. 2A), some Gpc3-deﬁcient animals had a
dilated LAD (Fig. 2B, arrowhead) feeding a coronary artery ﬁstula (Fig.
2B) that coursed through the interventricular septum and drained
into the right ventricle (Fig. 2C, arrowhead). Congenital heart defects
have frequently been described in mouse models, but coronary artery
ﬁstulas have rarely been reported (Li et al., 2002; Ratajska et al.,
2005). We therefore concluded that Gpc3 plays an important role incoronary vascular development. This novel foothold into the molec-
ular basis of coronary artery ﬁstulas motivated us to investigate the
developmental and signaling mechanisms related to Gpc3 function in
coronary development.
Loss of Gpc3 expression causes delayed development of the coronary
vascular plexus
We evaluated the timing and progression of the development of
the coronary vascular plexus by whole-mount immunohistochemical
Fig. 2. Gpc3-deﬁcient hearts display coronary artery ﬁstulas. The proximal left anterior
descending (LAD) and circumﬂex (CIRC) arteries are shown in a wild-type mouse (A).
(B and C) A coronary artery ﬁstula from a Gpc3/Y mouse. The proximal portion of the
ﬁstula shows a dilated LAD (arrowhead, B) feeding a coronary artery ﬁstula (CAF) that
courses through the interventricular septum ultimately draining into the right ventricle
(arrowhead, C). Although the connection to the right ventricle appears small in the
ﬁxed specimen, the shunt volume in the animal must have been large enough to cause
signiﬁcant coronary artery dilatation. Scale bar, 500 μm.
Fig. 3. Gpc3-deﬁcient hearts exhibit a delayed development of the coronary vascular
plexus. Whole-mount PECAM staining of E13.5 hearts demonstrated that when
compared to the vascular plexus of wild-type control hearts (A), Gpc3-deﬁcient hearts
(B) display delayed development of the coronary vascular plexus. Arrows indicate the
extent of the vascular plexus progression down the ventricle. (C) Quantiﬁcation of the
percentages of the ventricle covered by blood vessels is shown from a single
representative litter containing ﬁve wild-type (97.2±1.7%) and ﬁve Gpc3-deﬁcient
animals (81.4±5.0%) (pb0.0001).
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lial cell adhesion molecule-1 (PECAM-1), a vascular marker. Blood
vessels normally emerge from the atrioventricular groove at
approximately E11.5, expand towards the apices of the left and
right ventricle through E12.5 and eventually cover the entire
ventricular surface by E13.5 (Lavine et al., 2006). Various heparin-
dependent growth factors, including FGF and SHH, are critical to the
initial formation of the plexus, and loss-of-function mutations in
these signaling pathways cause a delay in its development (Lavine
et al., 2006). Compared to wild-type littermate controls, Gpc3-
deﬁcient hearts show a nearly identical delay in the development of
the coronary vascular plexus (Figs. 3A and B). To quantify the delay,
the percentage of the ventricles covered by blood vessels was
measured in collections of wild-type and Gpc3-deﬁcient animals
from a total of ﬁve different litters. Although variation existed
between individual litters in the overall magnitude of delay in
coronary vascular plexus formation, a consistent delay was observed
between the mutant and wild-type embryos within a litter. The
Gpc3-deﬁcient vascular plexus covered an average of 46.6–84.1%
of the heart, compared to 91.5–97.2% in the wild-type litter-
mates. The results from a representative litter are shown. In this
litter 97.2±1.7% of the ﬁve wild-type hearts were covered withvessels at E13.5, compared to 81.4±5.0% (pb0.0001) for the ﬁve
Gpc3-deﬁcient hearts (Fig. 3C).
Gpc3-deﬁcient hearts express reduced levels of Sonic Hedgehog
(Shh) mRNA
Several heparan sulfate-dependent growth factors have been
shown to be critical for normal coronary vascular development and
as such could be responsible for the observed phenotype in Gpc3-
deﬁcent animals. In particular, FGF9 has been shown to be critical to
coronary artery development. Like all FGFs, FGF9 requires a heparan
sulfate proteoglycan to form an active ternary signaling complex
(Lavine et al., 2006). FGF9 functions indirectly in coronary artery
development through the actions of Sonic Hedgehog (SHH), secreted
by the epicardium as a consequence of FGF9 signaling. Mice deﬁcient
for Fgf9 displayed a reduction in Shh mRNA expression and a
reduction in SHH signaling as revealed by a reduction in the mRNA
expression of Patched1 (Ptc1), a component of the SHH signaling
complex and a direct target gene for SHH. The reduction in SHH signal
strength is responsible for the delay in coronary vascular plexus
formation (Lavine et al., 2006).
The delay in coronary vascular plexus formation in Fgf9 null
animals is nearly identical to the phenotype we observed in Gpc3-
deﬁcient animals. Therefore, to characterize the potential relationship
Fig. 4. Shh mRNA levels are decreased in Gpc3-deﬁcient hearts. Whole-mount in situ hybridization at embryonic day 12.5 demonstrates that mRNA levels of Shh are signiﬁcantly
decreased in Gpc3-deﬁcient hearts (B) compared to wild-type controls (A).
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we evaluated the level of expression of Shh mRNA levels by whole-
mount in situ hybridization in wild-type and Gpc3-deﬁcient animals.
Shh mRNA expression was diminished in hearts that lacked
expression of Gpc3 compared to wild-type controls (Fig. 4), similar
to Fgf9-deﬁcient animals, and consistent with a function of GPC3 as a
co-receptor for FGF9 signaling.
Loss of Gpc3 function selectively reduces SHH signaling by
cardiomyocytes with relatively preserved signaling within the
perivascular cells
A reduction in Shh mRNA expression does not necessarily
conﬁrm a reduction in SHH protein levels, or more speciﬁcally the
level or strength of SHH signaling. The reduction in SHH mRNA
expression in Fgf9-deﬁcient animals causes a reduction in Ptc1
mRNA expression, a component of as well as a direct target of the
SHH signaling pathway, and therefore directly conﬁrms a reduction
in SHH signaling. We found a similar reduction in Ptc1 mRNA
expression in Gpc3-deﬁcient hearts by whole-mount in situ
hybridization (data not shown), but unlike Fgf9-deﬁcient animals
the reduction in Ptc1 expression was cell-type speciﬁc. Although
SHH signaling, as assessed by Ptc1 mRNA in situ expression at
E13.5, is markedly reduced in the cardiomyocytes of Gpc3-deﬁcient
hearts, signaling is relatively preserved in the perivascular cells
(Figs. 5B and C). The observation that SHH signaling is asymmet-
rically altered in Gpc3-deﬁcient hearts, while surprising, is consis-
tent with and may well explain the complex phenotype of coronary
artery ﬁstulas in Gpc3-deﬁcient animals as described below.Fig. 5. Ptc1mRNA expression is reduced in cardiomyocytes, but preserved in the perivascula
sections of embryonic day 13.5 wild-type (A) and Gpc3-deﬁcient hearts (B) reveals that alth
there is relatively preserved expression by perivascular cells responsible for the formation of
expression of Ptc1 cytoplasmic mRNA in cells with perivascular localization (arrows). RedLoss of Gpc3 alters the relative abundance of coronary arteries and veins
The impairment of the FGF/SHH signaling axis in the embryonic
hearts of Gpc3-deﬁcient animals can explain the delayed formation of
the coronary vascular plexus but does not by itself explain the
pathogenesis of coronary artery ﬁstulas. Somehow, the ﬁstulas must
arise from an inability of arterial progenitors to connect to the venous
system, which could result from a defect in any number of processes
like cell-type speciﬁcation or cell–cell communication. Coronary
arteries are well established to develop from vessels deep within
the myocardium, while the veins arise and are localized superﬁcially
in the subepicardium (Lavine et al., 2008b; Ratajska et al., 2003), and
Shh signaling in perivascular cells and cardiomyocytes, respectively,
speciﬁes the development of these coronary arteries and veins in their
distinct histological locations (Lavine et al., 2008b). The differential
effects of the loss of Gpc3 function on SHH signaling in cardiac
myocytes in contrast with perivascular cells, as demonstrated above,
would be expected to lead to an asymmetrical development of the
coronary arteries and veins. To address this issue, we examined and
counted intramyocardial and subepicardial vessels in representa-
tive 400× ﬁelds of view from sections at the bases of PECAM-stained,
E13.5 Gpc3-deﬁcient and wild-type hearts. Representative sections
clearly showed an increased number of PECAM-stained cells in
the myocardium of Gpc3-deﬁcient hearts compared to wild-type
(Figs. 6A and B). There were approximately ﬁve times as many intra-
myocardial (arterial) vessels in the mutant as in the wild-type,
whereas the number of subepicardial (venous) vessels tended to be
less (Fig. 6C). Therefore, loss of Gpc3 function causes a disproportion-
ate increase in the number of coronary arteries relative to veins. Givenr cells of Gpc3-deﬁcient animals. In situ hybridization detection of Ptc1mRNA in tissue
ough there is an overall reduction in Ptc1 mRNA expression in Gpc3-deﬁcient animals,
coronary arteries (arrows). Higher magniﬁcation view of Gpc3-deﬁcient heart showing
cells (arrowheads) in the vascular lumen (asterisks) are as marked.
Fig. 6. Loss of Gpc3 expression results in an increase in the number of intramyocardial
vessels. Whole-mount PECAM-stained hearts were sectioned and then counterstained
with hematoxylin. The coronary veins are found in the subepicardial layer noted in (A)
and (B) by arrows, while coronary arteries are found in the intramyocardial layer
demarked by the arrowhead in (B). As shown quantitatively (C), there is a signiﬁcant
increase in the number of intramyocardial vessels in Gpc3-deﬁcient hearts compared to
wild-type hearts. Sections were photographed at 400×.
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in some animals to a cardiac chamber to form a ﬁstula.
Discussion
A high incidence of congenital heart defects is found in SGBS in
association with the loss of function of the heparan sulfate
proteoglycan (HSPG) known as Gpc3. HSPGs in general, and glypicans
in particular, are widely expressed and function as critical modulatorsof a diverse array of signaling pathways during development. These
include FGFs, Hedgehogs, Wnts and BMPs (Filmus et al., 2008)
pathways that have all been implicated in the pathogenesis of
congenital heart malformation (Andelﬁnger, 2008). FGF and Hedge-
hog signaling, in particular, function in the development of the cardiac
outﬂow tract and atrioventricular canal, and the absence of Gpc3
expression in the developing heart and associated tissues likely
contributes to the heart defects observed in our mouse model
(Goddeeris et al., 2008; Goddeeris et al., 2007; Hutson et al., 2006;
Park et al., 2008). Although coronary vascular abnormalities have not
been speciﬁcally described in SGBS, there has been a case report
describing clinically signiﬁcant abnormalities of the carotid artery
(Penisson-Besnier et al., 2008) suggesting the importance of studying
Gpc3 to understanding the biology of vascular development. The
unanticipated discovery of coronary artery ﬁstulas in Gpc3-deﬁcient
mice offers novel insight into the molecular basis of coronary
development.
Although the phenotypes observed on this C57Bl6 inbred strain
display incomplete penetrance and variable expressivity, this obser-
vation is neither surprising nor is it a contradiction to the conclusion
that Gpc3 is critical to these aspects of cardiac development.
Variability in both penetrance and expressivity is a well established
observation in association with other genetic mutations resulting in
cardiac developmental defects in inbred strains, and speaks to the
important role of epigenetic inﬂuences and stochastic events in the
phenotypic presentation of cardiac defects (Black, 2006). Similarly,
we would anticipate, as in the case of other phenotypes previously
observed in association with loss of Gpc3 function (Cano-Gauci et al.,
1999; Chiao et al., 2002; Paine-Saunders et al., 2000), that there is
strain-speciﬁc variability reﬂective of the important role of genetic
modiﬁers. However, exploration of these various factors was not the
focus of the present study.
Development of the vasculature typically begins in most tissues
with the formation of a primary capillary plexus via the process of
vasculogenesis, which is then remodeled through a process of
angiogenesis (Flamme et al., 1997; Risau, 1997). During the remodel-
ing process, the various caliber arterial and venous vessels emerge
permitting blood to ﬂow from the arteries to the arterioles, capillaries,
venules and ﬁnally veins. The coronary vascular system follows a
similar sequence of development, which is tightly regulated by a
cascade of growth factor signals. The epicardium has been identiﬁed
as a critical modulator of this development because removal of the
epicardium results in the loss of signaling molecules critical to the
initiation of this cascade and therefore defects in coronary develop-
ment (Morabito et al., 2002; Reese et al., 2002; Wada et al., 2003).
FGF9 released from the epicardium signals through FGF receptors on
the cardiomyocytes to result in the release of a wave of Shh expression
by the epicardium (Lavine et al., 2006). This in turnmodulates via Vegf
the wave of growth and development of the coronary vascular plexus
as it originates in the atrial–ventricular groove and extends toward
the ventricular apices (Lavine et al., 2006). Loss of either Fgf9
expression by the epicardium or conditional loss of both Fgfr1 and
Fgfr2 receptor expression by the cardiomyocytes results in a delay
in formation of the coronary vascular plexus identical to what we
observed for Gpc3 mutants (Lavine et al., 2006).
One of the many functions of HSPGs is as an essential co-receptor
for FGF signal transduction (Rapraeger et al., 1991; Yayon et al., 1991).
Although heparan sulfate (HS) carbohydrate chains of HSPGs bind
FGFs with low afﬁnity, this low afﬁnity interaction promotes the
formation of a higher afﬁnity complex between FGFs and their
tyrosine kinase signaling receptors FGFR1–FGFR4 (Nugent and Edel-
man, 1992; Roghani et al., 1994). While the precise stoichiometry and
mechanism of this functional interaction remains an issue of active
investigation (Goodger et al., 2008), it is well established that HS
binds to both FGFs (Ornitz et al., 1995) and the FGF receptors (Kan et
al., 1993) thus increasing the afﬁnity of FGFs for their signaling
214 A. Ng et al. / Developmental Biology 335 (2009) 208–215receptors and are therefore essential for receptor dimerization and
subsequent signaling (Herr et al., 1997; Pantoliano et al., 1994;
Springer et al., 1994; Venkataraman et al., 1996).
Glypican family members are capable of augmenting FGF signaling
both in in vitro and in vivo systems (Aikawa et al., 2008; Bashkin et al.,
1992; Bonneh-Barkay et al., 1997; Brunner et al., 1991; Lai et al., 2008;
Steinfeld et al., 1996; Yan and Lin, 2007); however, little is known
about the normal functional relationships between speciﬁc glypicans
and speciﬁc FGF ligand/receptor pairs during development. Gpc3 is
co-expressed with the Fgfr1 and Fgfr2 receptors of the cardiomyocytes
required for the reception and subsequent relay of the FGF9 signals
responsible for the control of coronary vascular development, and loss
of function of Gpc3 in these same cells mimics the loss of Fgf9 function
with respect to both the induction of Shh mRNA expression and the
resulting progression of development of the coronary vascular plexus.
These ﬁndings are most readily explained by GPC3 providing an
essential co-receptor function for FGF9 in these cells, although we can
not exclude the possibility that loss of Gpc3 expression interferes with
other heparin-dependent cellular process that independently down-
regulates Shh mRNA expression in the heart.
While loss of Gpc3 function by the cardiomyocytes mimics the
phenotype of loss of Fgf9 function with respect to the initiation and
progression of the vascular plexus, we also found an imbalance
between the formation of coronary arteries and veins that is not seen
in association with either the loss of Fgf9 function or a generalized
reduction in Shh mRNA induction alone. Anatomical studies using
corrosion casting of late gestation hearts have unambiguously
demonstrated that coronary arteries and veins can be identiﬁed by
their development within distinct regions of the heart (Ratajska et al.,
2003). Using the conditional disruption of SHH signal reception and
speciﬁc molecular markers distinguishing coronary arteries and veins,
the Ornitz laboratory have furthermore conﬁrmed that coronary
arteries develop deep within the myocardial wall in response to SHH
signal reception within the perivascular cells, while coronary veins
formmore superﬁcially in the subepicardial region in response to SHH
signaling to the cardiomyocytes (Lavine et al., 2008b). Our results
clearly show that loss of Gpc3 function results in a disproportionate
accumulation of coronary arteries as compared with veins, an
alteration that we speculate is responsible ultimately for the routing
of these excess coronary arteries to the cardiac chamber, and thus the
formation of the coronary artery ﬁstulas we observed in Gpc3-
deﬁcient animals.
The imbalance between artery and vein formation in Gpc3-
deﬁcient animals would imply that although there is an overall
reduction in Shh mRNA expression, SHH signaling is disproportion-
ately reduced in the cardiomyocytes of Gpc3-deﬁcient mice as
compared with perivascular cells, a result conﬁrmed by the
examination of Ptc1 mRNA expression in Gpc3-deﬁcient hearts. We
do not know at the moment the molecular details by which the loss of
Gpc3 function might lead to differential SHH signaling between these
two populations of cells in the heart. Although the Filmus Lab has
recently provided evidence for alternative functions of GPC3 including
a direct inhibitory activity of GPC3 on SHH signaling in other tissues, a
similar activity in the heart would not explain our results. We found
that loss of Gpc3 function causes a reduction in ShhmRNA expression
and a reduction in SHH signaling in cardiomyocytes. Gpc3 is widely
expressed by cardiomyocytes, and loss of a SHH-inhibitory function in
these cells would be expected to result in an increase in SHH signaling
in those cells, rather than a reduction, and therefore an accelerated
rate of vascular plexus formation and a relative excess in vein
formation over arteries. Preserved and/or disproportionate SHH
signaling in perivascular cells in the setting of a reduction in the
production of SHH by the epicardium could be a reﬂection of
enhanced diffusion of SHH in the absence of GPC3 on the surface of
the cardiomyocytes. In addition and/or alternatively, loss of Gpc3
function might lead to the unopposed promotion of SHH signaling inperivascular cells by a different HSPG that actually promotes SHH
signaling, perhaps another member of the glypican gene family. The
Drosophila glypican Dally-like, for example, has been shown to
actually promote Hedgehog signaling in ﬂies (Beckett et al., 2008;
Gallet et al., 2008), and the vertebrate ortholog of this glypican, Gpc6,
is also expressed in the developing heart (data not shown). Further
studies will be necessary to distinguish between these alternative
hypotheses.
Our results provide the ﬁrst evidence of a role for GPC3 in vascular
development and speciﬁcally an important novel insight into the
molecular mechanisms of coronary artery ﬁstula formation. Further-
more, appreciating the role of GPC3 in coronary vascular development
has potentially broad clinical implications beyond understanding the
development of coronary arteryﬁstulas including, speciﬁcally, a potential
relationship to the prevention and treatment of ischemic heart disease.
Recent attempts at developing pharmacological approaches towards the
prevention and/or treatment of ischemic disease of the heart, a major
source of morbidity and mortality in humans, have included the
administration of either FGF or VEGF-A. While promising in animal
models, these approaches have thus far shown little efﬁcacy in humans
(Henry et al., 2000; Losordo et al., 2002; Simons et al., 2002). More
recently, temporal and tissue-speciﬁc disruption of SHH function in the
adult heart in vivo has been found to result in a loss of the normal
homeostatic maintenance of the coronary vasculature that results in
ischemic injury (Lavine et al., 2008a),while activation of SHH signaling in
vivo is sufﬁcient to promote coronary neovascularization and to be
protective against ischemia (Kusano et al., 2005). Together, these
observations suggest that the SHH signaling pathway may be a useful
target for the treatment of ischemic heart disease and that GPC3 may be
one potential target for therapeutic intervention.
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